Cyclo Therapeutics (CYTH) Earnings Date, Estimates & Call Transcripts $0.71 +0.03 (+4.42%) (As of 11/20/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Cyclo Therapeutics Latest Earnings SummaryLatest Earnings DateAug. 15EstimatedActual EPS (Aug. 15) -$0.21 Missed By -$0.07 Consensus EPS (Aug. 15) -$0.14 Cyclo Therapeutics announced Q2 2024 earnings on August 15, 2024, reporting an EPS of -$0.21, which missed the consensus estimate of -$0.14 by $0.07. Quarterly revenue was reported to be $0.12 million, below analyst estimates of $0.40 million. With a trailing EPS of -$0.90, Cyclo Therapeutics' earnings are expected to decrease next year, from ($0.72) to ($0.75) per share. Get Cyclo Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cyclo Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataCYTH Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CYTH Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Porter & CompanyFinancial Prophecy The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. Cyclo Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241-$0.20-$0.20-$0.20Q2 20241-$0.16-$0.16-$0.16Q3 20241-$0.16-$0.16-$0.16Q4 20241-$0.14-$0.14-$0.14FY 20244-$0.66-$0.66-$0.66Q1 20251-$0.14-$0.14-$0.14Q2 20251-$0.12-$0.12-$0.12Q3 20251-$0.13-$0.13-$0.13Q4 20251-$0.13-$0.13-$0.13FY 20254($0.52)($0.52)($0.52) Cyclo Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks8/15/2024--$0.14-$0.21 -$0.07-$0.21$0.40M$0.12M5/15/2024Q1 2024-$0.20-$0.15+$0.05-$0.15$0.44M$0.20M3/18/2024Q4 2023--$0.23 -$0.23-$0.23-$0.31M11/14/2023Q3 2023--$0.29 -$0.29-$0.29-$0.50M8/15/2023Q2 2023--$0.33 -$0.33-$0.33-$0.12M5/15/2023Q1 2023--$0.46 -$0.46-$0.46-$0.15M Get the Latest News and Ratings for CYTH and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cyclo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 3/17/2023Q4 2022-$0.25-$0.59 -$0.34-$0.59-$0.19M Cyclo Therapeutics Earnings - Frequently Asked Questions When did Cyclo Therapeutics announce their last quarterly earnings? Cyclo Therapeutics (NASDAQ:CYTH) last announced its quarterly earning data on Thursday, August 15, 2024. Learn more on CYTH's earnings history. Did Cyclo Therapeutics beat their earnings estimates last quarter? In the previous quarter, Cyclo Therapeutics (NASDAQ:CYTH) missed the analysts' consensus estimate of ($0.14) by $0.07 with a reported earnings per share (EPS) of ($0.21). Learn more on analysts' earnings estimate vs. CYTH's actual earnings. How much revenue does Cyclo Therapeutics generate each year? Cyclo Therapeutics (NASDAQ:CYTH) has a recorded annual revenue of $870,725.00. How much profit does Cyclo Therapeutics generate each year? Cyclo Therapeutics (NASDAQ:CYTH) has a recorded net income of -$20.06 million. CYTH has generated -$0.90 earnings per share over the last four quarters. What is Cyclo Therapeutics's EPS forecast for next year? Cyclo Therapeutics's earnings are expected to decrease from ($0.72) per share to ($0.75) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies IKNA Earnings Results QNCX Earnings Results CLSD Earnings Results CMRX Earnings Results FBLG Earnings Results IMAB Earnings Results AVTE Earnings Results EPIX Earnings Results PDSB Earnings Results HOWL Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report Financial Prophecy (Ad)The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. This page (NASDAQ:CYTH) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
